Cosmo Pharmaceuticals N.V.

LSE:0RGI Stock Report

Market Cap: CHF 982.0m

Cosmo Pharmaceuticals Valuation

Is 0RGI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RGI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0RGI (CHF60.2) is trading below our estimate of fair value (CHF714.24)

Significantly Below Fair Value: 0RGI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RGI?

Key metric: As 0RGI is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0RGI. This is calculated by dividing 0RGI's market cap by their current earnings.
What is 0RGI's PE Ratio?
PE Ratio15.1x
Earnings€69.57m
Market Cap€1.05b

Price to Earnings Ratio vs Peers

How does 0RGI's PE Ratio compare to its peers?

The above table shows the PE ratio for 0RGI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.3x
HIK Hikma Pharmaceuticals
19.4x12.2%UK£4.4b
ANCR Animalcare Group
31.1x5.3%UK£143.7m
EAH ECO Animal Health Group
73.1x39.2%UK£48.1m
GSK GSK
21.8x23.2%UK£54.7b
0RGI Cosmo Pharmaceuticals
15.1x17.2%CHF 982.0m

Price-To-Earnings vs Peers: 0RGI is good value based on its Price-To-Earnings Ratio (15.1x) compared to the peer average (36.3x).

Price to Earnings Ratio vs Industry

How does 0RGI's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
0RGI 15.1xIndustry Avg. 19.5xNo. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0RGI is good value based on its Price-To-Earnings Ratio (15.1x) compared to the European Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is 0RGI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RGI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio15.1x
Fair PE Ratio21.8x

Price-To-Earnings vs Fair Ratio: 0RGI is good value based on its Price-To-Earnings Ratio (15.1x) compared to the estimated Fair Price-To-Earnings Ratio (21.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RGI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCHF 60.20
CHF 97.30
+61.6%
22.2%CHF 132.49CHF 78.92n/a4
Dec ’25CHF 62.80
CHF 97.30
+54.9%
22.2%CHF 132.49CHF 78.92n/a4
Nov ’25CHF 68.40
CHF 97.19
+42.1%
23.0%CHF 133.30CHF 76.59n/a4
Oct ’25CHF 75.00
CHF 96.89
+29.2%
23.1%CHF 132.99CHF 76.32n/a4
Sep ’25CHF 79.90
CHF 97.14
+21.6%
22.9%CHF 132.96CHF 76.63n/a4
Aug ’25CHF 74.90
CHF 97.14
+29.7%
22.9%CHF 132.96CHF 76.63n/a4
Jul ’25CHF 71.10
CHF 93.19
+31.1%
15.2%CHF 112.82CHF 78.44n/a4
Jun ’25CHF 70.40
CHF 93.09
+32.2%
13.5%CHF 109.09CHF 79.54n/a4
May ’25CHF 72.30
CHF 93.09
+28.8%
13.5%CHF 109.09CHF 79.54n/a4
Apr ’25CHF 71.30
CHF 93.00
+30.4%
13.7%CHF 109.38CHF 79.27n/a4
Mar ’25CHF 66.64
CHF 75.96
+14.0%
10.0%CHF 83.49CHF 65.58n/a3
Feb ’25CHF 62.19
CHF 75.96
+22.1%
10.0%CHF 83.49CHF 65.58n/a3
Jan ’25CHF 51.30
CHF 73.12
+42.5%
11.3%CHF 84.75CHF 66.58n/a3
Dec ’24CHF 42.35
CHF 73.36
+73.2%
10.7%CHF 84.41CHF 67.77CHF 62.803
Nov ’24CHF 35.20
CHF 73.97
+110.2%
10.6%CHF 85.09CHF 68.37CHF 68.403
Oct ’24CHF 40.25
CHF 73.97
+83.8%
10.6%CHF 85.09CHF 68.37CHF 75.003
Sep ’24CHF 44.02
CHF 68.10
+54.7%
17.2%CHF 85.12CHF 52.03CHF 79.904
Aug ’24CHF 44.79
CHF 74.16
+65.6%
10.1%CHF 85.55CHF 66.89CHF 74.904
Jul ’24CHF 45.90
CHF 77.41
+68.6%
7.9%CHF 85.09CHF 67.97CHF 71.104
Jun ’24CHF 47.09
CHF 80.45
+70.8%
12.9%CHF 96.55CHF 67.59CHF 70.404
May ’24CHF 53.90
CHF 80.45
+49.3%
12.9%CHF 96.55CHF 67.59CHF 72.304
Apr ’24CHF 56.80
CHF 81.83
+44.1%
12.6%CHF 97.03CHF 67.93CHF 71.304
Mar ’24CHF 60.30
CHF 81.70
+35.5%
12.8%CHF 97.22CHF 67.99CHF 66.644
Feb ’24CHF 67.20
CHF 83.59
+24.4%
12.3%CHF 99.80CHF 71.50CHF 62.194
Jan ’24CHF 61.68
CHF 83.61
+35.6%
13.7%CHF 98.40CHF 70.50CHF 51.303
Dec ’23CHF 62.80
CHF 84.07
+33.9%
16.5%CHF 97.95CHF 70.18CHF 42.352

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 14:15
End of Day Share Price 2024/12/23 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cosmo Pharmaceuticals N.V. is covered by 14 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Laura Pfeifer-RossiBank am Bellevue
Silvia SchanzBank Vontobel AG
Laura HindleyBerenberg